Medicine

Nuclera has appointed Seth Benson as Chief Financial Officer Nuclera, the biotechnology company accelerating protein expression and optimisation through its benchtop eProtein Discovery system, has announced

iOnctura has appointed Elizabeth Holt as Chief Business Officer iOnctura has announced the appointment of Elizabeth Holt, former Co-Founder of Aiolos Bio, as its

Pfizer’s Abrysvo is designed to prevent RSV-associated disease in infants The World Health Organization (WHO) has announced that it has added Pfizer’s maternal respiratory

Collaboration brings remote care to cancer patients Careology and Entia have announced a partnership to enhance cancer care through innovative digital and at-home solutions.

How to choose the best telemedicine provider for neurology As hospitals navigate the evolving landscape of healthcare, telemedicine has emerged as a viable solution

Aragen has appointed Manjunath Ramarao as Chief Scientific Officer Aragen has announced the appointment of Manjunath Ramarao as Chief Scientific Officer (CSO) and Executive

The update is aimed at strengthening local and national surveillance The UK Health Security Agency (UKHSA) has announced that it has expanded the list

Elekta has appointed Jonas Bolander as Acting President and CEO Elekta has announcement the appointment of Jonas Bolander as Acting President and Chief Executive

The company is preparing to submit the results to the FDA this year Orca Bio has shared promising results from a late-stage study of

Abzena has appointed Taylor Boyd as Chief Business Officer Abzena has announced the appointment of Taylor Boyd to the newly created role of Chief

The agency has launched a whole genome sequencing service to monitor the virus The UK Health Security Agency (UKHSA) has announced the launch of

Top 5 platforms for measurement-based care in 2025 Measurement-based care (MBC) enhances clinical and therapeutic outcomes through client-reported data and evidence collection. MBC systems

VIDAR-1 trial marks company’s clinical-stage debut Anocca has achieved regulatory approval for its first clinical trial, VIDAR-1, a major milestone in the company’s transition

Immunoglobulin therapy improves mobility in phase 2/3 study Grifols has announced positive results from its phase 2/3 clinical trial evaluating the efficacy and safety

EC extends brexpiprazole indication to include adolescents Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for the

Company seeks new direction after negative CHMP opinion on KIZFIZO Orphelia Pharma is exploring alternative regulatory pathways for KIZFIZO after receiving a negative opinion

Phase 2a TREE study assesses safety and efficacy of leriglitazone Minoryx Therapeutics has dosed the first patient in its phase 2a TREE study, which

Oxford Medical Products targets overweight individuals Oxford Medical Products has announced positive three-month clinical trial results for Sirona, a weight-loss treatment aimed at overweight

CervoMed’s therapy demonstrates significant improvement in patients CervoMed has announced positive results from the extension phase 2b RewinD-LB study of neflamapimod for dementia with

Scottish Medicines Consortium approves new option for mCRPC patients Pfizer Ltd has announced that the Scottish Medicines Consortium (SMC) has accepted Talzenna (talazoparib) in

FSCD therapy meets all endpoints in interim analysis Agomab Therapeutics NV (Agomab) has announced positive interim results from 44 patients completing treatment in the

Octapharma supports NHS in building resilient supply chain Octapharma has announced that, for the first time in almost 30 years, NHS patients are receiving

NICE convenes third committee meeting for additional appraisal consideration Eisai Europe Ltd. and Biogen Idec Ltd. announced that NICE will convene a third appraisal

Innovative digital transformation leads to significant improvements To reduce waiting lists and enhance patient communication, Rotherham NHS Foundation Trust has adopted Netcall’s Liberty for

Cohort expansion phase commences with promising results The Safety Review Committee (SRC) has confirmed the end of the Dose Escalation phase and the start

Lead candidate for lung infections moves to human trials Centauri Therapeutics Limited has announced the selection of its first clinical candidate for the ABX-01

Kenvue appoints Bas Vorsteveld as Managing Director for Northern Europe Kenvue has appointed Bas Vorsteveld as Area Managing Director for Northern Europe. He will oversee Kenvue’s business in the

New research highlights NHS approval gap compared to other cancers Research from the Blood Cancer Alliance reveals a significant disparity in access to new

Grünenthal has appointed Professor Dr Uli Brödl as CSO Grünenthal has announced that Professor Dr Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the

Pharmaceutical manufacturers in the UK have been navigating complex supply chains for the longest time, balancing the dual pressures of meeting patient needs and

The critical step of navigating post-approval phase

New collaboration aims to integrate AI solutions for treatment Brainomix, a leader in stroke AI imaging software, has announced a strategic partnership with Medtronic

New partnership to integrate SRD search technology Datapharm, a UK-based provider of medicines information, has announced its expansion into Europe through a strategic partnership

Updated data from phase 2 study reveals survival benefit Alligator Bioscience has announced updated results from its phase 2 OPTIMIZE-1 study, showing the survival

Data presented in Los Angeles showcases therapy’s potential Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting

Awareness of interstitial lung disease raised at Miracle Garden Boehringer Ingelheim, a leading biopharmaceutical company, has teamed up with the Emirates Thoracic Society (ETS)

Former UK PM advocates for national screening programme Rishi Sunak has joined Prostate Cancer Research as an ambassador to champion the charity’s campaign for

BC Platforms has appointed Mukhtar Ahmed as CEO BC Platforms has announced that it has appointed Mukhtar Ahmed as its new Chief Executive Officer

It is hoped that the approach will lead to more targeted treatments for childhood cancers Researchers from the Institute of Cancer Research (ICR) have

Carbogen Amcis has appointed Stephan Fritschi as CEO Carbogen Amcis has appointed Stephan Fritschi, who is currently serving as the company’s Chief Alliance Officer

Tenosynovial giant cell tumours can cause pain, stiffness, swelling and movement limitations The US Food and Drug Administration (FDA) has approved Deciphera Pharmaceuticals’ Romvimza

Baxter has appointed Brent Shafer as Chair and Interim CEO Baxter International has appointed Brent Shafer, who has been serving as the company’s Lead

The common heart condition affects approximately 1.5 million people in the UK A new UK study has highlighted the critical role of GP data

Baxter has appointed Heather Knight as Executive Vice President and COO Baxter International has appointed Heather Knight, who has been leading the company’s Medical

New data has shown that around a third of women do not attend screenings after being invited NHS England has launched its first-ever breast

New funding to investigate cognitive decline and brain ageing The University of Bath has received a £3.5 million Wellcome grant to study cognitive decline

New test aims to revolutionise prostate cancer screening Scientists in Cambridge have developed a new ‘super test’ for prostate cancer to improve screening, diagnosis

Imaging agent to improve prostate cancer detection Telix Pharmaceuticals has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the

Significant progress for hereditary angioedema condition Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY (garadacimab), the first once-monthly

UCB’s BIMZELX reveals promising two-year data at EHSF 2025 UCB has announced impressive two-year data for BIMZELX (bimekizumab) at the 2025 EHSF. The data

Potential treatment for multiple system atrophy shows promise Lundbeck’s investigational drug, amlenetug, has been granted Fast Track Designation by the US Food and Drug

Treatment expands options for HER2-negative metastatic breast cancer AstraZeneca announced that its drug Lynparza (olaparib) has been approved for use in Scotland. The approval

New immunotherapy offers hope for recurrent cervical cancer Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for

CSL Behring’s study reveals significant long-term benefits New data from CSL Behring’s HOPE-B study demonstrates that Hemgenix (etranacogene dezaparvovec-drlb) gene therapy provides sustained efficacy

New methodology may boost innovation in protein engineering Capgemini has introduced a pioneering generative AI-driven methodology for protein engineering, utilising a specialised protein large

Designation follows promising preclinical data and FDA clearance Ariceum Therapeutics, a private biotech company based in Berlin, has announced that the US Food and

Partnership aims to leverage cutting-edge technology in clinical trials Qureight Ltd and Avalyn Pharma Inc have announced a strategic partnership in progressive pulmonary fibrosis

Breast cancer therapy offers hope for patients at risk of recurrence Novartis UK announced the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised

Sanofi’s Rippon Ubhi appointed new Chair of European Medicines Group Sanofi has announced that Rippon Ubhi has been appointed as the new Chair of the European Medicines

Study shows AP-325 offers lasting pain relief without central side effects Algiax Pharmaceuticals, a company committed to developing innovative treatments for chronic neuropathic pain,

Partnership aims to create recombinant nanobodies to treat immune disorders Grifols, a global healthcare company and leading manufacturer of plasma-derived medicines, has announced a

Positive opinion issued for marketing authorisation extension The Committee for Medicinal Products for Human Use (CHMP) has recommended extending marketing authorisation for a subcutaneous

Funding led by new investors FSG and EIC Fund Helsinki-based Aplagon has raised EUR 7 million to advance its APAC therapeutic for thrombo-inflammatory diseases

Comparison shows improved survival rates for pancreatic cancer treatment Alligator Bioscience has announced positive outcomes from indirect treatment comparison studies, showing that mitazalimab combined

How the emc supports the accessibility of medicines information Distributing reliable information about medicines is challenging for the pharma industry and the healthcare professionals

Diversity remains high on the agenda for those designing and delivering clinical trials with the aim of bringing new treatments and medicines to market.

Commit Biologics has appointed Janine Schuurman to its board Commit Biologics has announced the appointment of Janine Schuurman to its Board of Directors. Janine is a widely recognised scientific

Alliance Healthcare has appointed Paula Sutherland as Sales Director Alliance Healthcare UK has announced that Paula Sutherland has been appointed to the position of Sales Director. Paula will lead

Patients and care partners may find once every four weeks maintenance dosing easier The US Food and Drug Administration (FDA) has approved a new

Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25 Cartesian Therapeutics has secured an agreement from the US Food and Drug

Study highlights VE303’s potential in reducing recurrent CDI Vedanta Biosciences has published additional results from its Phase 2 CONSORTIUM study for VE303, a potential

NICE endorses Imfinzi and Tagrisso for enhanced lung cancer care AstraZeneca has received two positive recommendations from the National Institute for Health and Care

Phase 3 trial shows promising pain relief for acute pain patients Tris Pharma, Inc. has announced positive results from its ALLEVIATE-1 phase 3 clinical

Orphan drug designation offers development incentives and potential market exclusivity Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast,

Europe’s first biomarker trial seeks to prevent Crohn’s Disease onset In a landmark effort, the INTERCEPT project has launched Europe’s first biomarker trial aimed

Combination therapy shows superior survival benefit over standard treatment The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with

Preclinical data highlights potential in treating Alzheimer’s disease AlzeCure Pharma AB announced that its abstract on NeuroRestore ACD856 has been accepted for presentation at

Cell and Gene Therapy Catapult reveals significant growth in UK trials The UK experienced a notable increase in advanced therapy clinical trials in 2024,

Collaboration aims to enhance accessibility of medicines information Datapharm has announced its expansion into the United States through a new partnership with phactMI. The

Companies aim to provide new treatments for inflammatory conditions Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral

Partnership aims to advance Alzheimer’s research with innovative tools Cambridge Cognition Holdings plc has expanded its partnership with Actinogen Medical Limited for the phase

New partnership to advance precision medicine in lung cancer diagnosis Biofidelity and CellCarta have announced a strategic partnership to utilise Biofidelity’s Aspyre® Lung in

Promising results from mouse study lead to expanded trials Oxford Drug Design, the Oxford-based AI drug discovery company, has announced further in vivo validation

Funds to accelerate commercialisation and clinical trials of diagnostic tests Owlstone Medical has announced a first close of $27 million (circa £22 million) in

Initiative aims to identify plasma-based biomarkers for early detection Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF)

First-in-human trial of PTD802 to commence following UK MHRA approval Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from the UK’s MHRA for

Companies aim to provide new treatments for inflammatory conditions Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral

Survey finds AI to enhance productivity and cut costs in the next 12 months AI is poised to significantly lower pharmaceutical R&D costs through

Groundbreaking approval provides new hope for patients in England and Wales The National Institute for Health and Care Excellence (NICE) has given a positive

CR-discovered NXP800 shows promise in clinical trials Prostate cancer resistant to hormone therapy could soon have a new treatment option. The Institute of Cancer

Investment to support RNA therapeutics for epilepsy and neurological disorders Angelini Ventures has co-led a €20 million Series A financing round in Neumirna Therapeutics.

New FDA-approved schizophrenia treatment shows promise in clinical trials Cambridge Cognition has praised Bristol Myers Squibb for the FDA approval of Cobenfy (KarXT), a

M-Trust set to improve product safety and counterfeiting solutions Merck has launched the beta version of M-Trust, a pioneering cyber-physical trust platform, at CES

OAV101 IT expands potential for type II SMA patients Novartis has announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) achieved the

IMDYLLTRA offers new hope for patients with extensive-stage small cell lung cancer The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a

EpiSwitch PSE shows promise in reducing unnecessary procedures Kearney Urology Center has reported a 50% reduction in biopsies since adopting EpiSwitch PSE, a new

Debra is late getting up for work again. In her heart of hearts, she’s not really enjoying her job as a teaching assistant in

FDA gives green light to innovative device for liver conditions Sequana Medical NV has announced the US FDA approval of its Alfapump system for

Government announces independent commission on social care The government has announced the creation of an independent commission on social care. The NHS Confederation has

MHRA urges caution over illegal medicines from beauty salons and social media The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding the public

New chemotherapy-free treatment shows promise for EGFR-mutated NSCLC Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved Rybrevant

New CT-guided radiotherapy system offers personalised cancer treatment Berlin’s Diagnostisch Therapeutisches Zentrum (DTZ) has become the first in the world to treat a patient

First patient dosed in landmark trial for GAD treatment MindMed has announced the dosing of the first patient in its phase 3 Voyage study

Phase 2a study shows promising antidepressant effects Beckley Psytech has announced positive topline results from its phase 2a study of ELE-101, a synthetic intravenous

New treatment could revolutionise care for HAE patients Global biotechnology leader CSL has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products

Promising trial results support marketing authorisation application Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone has met the primary endpoint in the NEXUS

Trial explores potential of therapy in treating multiple cancer types Bayer has begun a phase 1 clinical trial for BAY3498264, an investigational oral selective

Promising results set stage for European marketing authorization Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone met the primary endpoint in the NEXUS

Successful phase 1 study highlights potential of roginolisib iOnctura has announced promising results from the phase 1 DIONE-01 study, showcasing the clinical activity and

New findings presented at international SCWD conference CatalYm has announced promising new data on its lead drug candidate, visugromab, at the 17th International Conference

New cell therapy shows potential in treating advanced blood disorder Cellenkos has unveiled new phase 1b data for its T-regulatory cell therapy candidate, CK0804,

promising pre-clinical data on preventing cytokine release syndrome Poolbeg Pharma has unveiled encouraging pre-clinical study data for POLB 001 at the 66th American Society

Trial results lead to new treatment option for lung cancer AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating

New antibody therapy shows promise in managing condition Neuraxpharm Group has announced that the National Institute for Health and Care Excellence (NICE) has recommended

Phase 3 trial indicates significant efficacy and safety for children and adolescents Teva Pharmaceutical Industries has presented positive data from its Phase 3 SPACE

Data highlights effectiveness of EVER001 in treating pMN Everest Medicines has announced promising results from the Phase 1b/2a clinical trial of EVER001, a novel

Versant Ventures leads investment round to advance drug Antag Therapeutics has announced the closing of an €80 million Series A financing round to develop

Partnership aims to develop new radiopharmaceuticals for cancer treatment Orbit Discovery, based in Oxford, UK, and Evergreen Theragnostics, headquartered in Springfield, NJ, USA, have

Immunocore has announced that Kimmtrak (tebentafusp) has been recommended for funding in England by the National Institute for Health and Care Excellence (NICE) and

Race to create first oral drug for obesity intensifies The competition to gain approval for the first oral GLP-1R drug for obesity is heating

New SureSeq CLL + CNV V3 panel improves understanding of CLL OGT has announced the launch of its enhanced SureSeq CLL + CNV V3

Therapy for autoimmune disorder shows potential Argenx’s investigational therapy, subcutaneous efgartigimod alfa, has been granted Promising Innovative Medicine (PIM) status by the UK Medicines

Injection significantly reduces need for further treatment A new treatment for asthma and COPD attacks could revolutionise patient care, scientists say. An injection given

2024 ABPI Code update has launched – what’s next for pharma and QR codes? The long-anticipated update to the ABPI Code of Practice has

Curve Therapeutics has appointed Rab Prinjha as Chief R&D Officer Curve Therapeutics has appointed Rab Prinjha as Chief Research and Development (R&D) Officer. Rab is a proven R&D leader with

How industry and the NHS can work together to bridge the diagnostic gap in COPD

How oncology therapies can stand out in a diverse, uncertain landscape The oncology field is rapidly evolving, particularly with the rise of precision medicines

Commit Biologics has appointed Mikkel Wandahl Pedersen as CSO Commit Biologics has announced the appointment of Mikkel Wandahl Pedersen as Chief Scientific Officer (CSO).

Tessellate BIO has appointed Dr Lara Boyd as CBO Tessellate BIO has appointed Dr Lara Boyd as Chief Business Officer. Lara joins Tessellate BIO from F-star

There’s no denying it; pharma is in its innovation era. The life sciences industry is already undergoing a massive revolution, thanks to the rapid

Mahony will continue as the UK government’s Life Sciences Investment Envoy The Department for Science, Innovation and Technology has announced that Dr Daniel Mahony

The biotech will use the funding to drive sales of its first commercial product Cytomos has announced that it has raised $5m in an

The MHRA has appointed Anthony Harnden as Chair The Medicine and Healthcare products Regulatory Agency (MHRA) has appointed Anthony Harnden, Professor of Primary Care

The Netherlands facility is designed to handle a wide range of nanomedicines, including lipid-based nanoparticles Ardena has announced the full Good Manufacturing Practice (GMP)

The King’s Fund has appointed Siva Anandaciva as Director of Policy, Events and Partnerships The King’s Fund has appointed Siva Anandaciva, its current Chief

The census found that 56% of people visit their GP for a UTI and 27% for thrush New research from PAGB has revealed that

Somerset NHS Foundation Trust has appointed Dr Rima Makarem as Chair Somerset NHS Foundation Trust has appointed Dr Rima Makarem, who has 15 years

The companies will focus on mechanisms of action, dose selection and biomarker analyses Teva Pharmaceuticals and artificial intelligence (AI)-driven Immunai have entered into a

Therapy shows high efficacy in initial trial phase AC Immune SA has reported encouraging interim results from its phase 2 VacSYn clinical trial of

First participant vaccinated in study of ovx836 booster dose Osivax, a biopharmaceutical company developing vaccines for broad-spectrum protection against infectious viruses, has vaccinated the

New long-term partnership to address neurological disorder treatments Vivolta, a specialist in medical electrospinning solutions, has entered a long-term partnership with UK-based Neurochase to

First patient dosed in phase 1b trial of MB310 therapy Microbiotica, a clinical-stage biopharma company, has announced the dosing of the first patient in

Insight into double-blind, phase i/ii clinical trial for oesophageal cancer Infinitopes, an integrated cancer biotech firm, will present its pioneering cancer vaccine development at

Eco-friendly inhalers aim to reduce environmental impact Lupin Healthcare UK Ltd has announced plans to reformulate its pMDI inhalers with a near-zero global warming

First car t-cell therapy accepted for second-line treatment in Scotland The Scottish Medicines Consortium (SMC) has approved Kite’s CAR T-cell therapy, Yescarta (axi-cel), for

New treatment option approved for women in Scotland The Scottish Medicines Consortium (SMC) has recommended Yselty (linzagolix) for treating moderate to severe symptoms of

New initiatives to tackle AI-related challenges in life sciences Elsevier, a leader in information and analytics, has announced its support for The Pistoia Alliance

Trial to evaluate safety and efficacy of MVA-BN vaccine A new scientific trial evaluating Bavarian Nordic’s mpox vaccine in pregnant and breastfeeding women and

New therapy targets specific genetic alterations, promises extended survival Johnson & Johnson has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA)

Phase 1 and 2 studies show promising results for anito-cel therapy Arcellx Inc, a biotechnology firm focused on cell therapy innovations, has announced impressive

AstronauTx has appointed Dr Jane Rhodes as Chief Executive Officer AstronauTx has appointed Dr Jane Rhodes as Chief Executive Officer (CEO) and member of the Board, and Magnus Ivarsson as Chief Translation

Importance of continuous collaboration with rare disease communities At Blueprint Medicines, we aim to make a significant difference in patients’ lives by solving critical

Building strong partnerships with sites for more effective clinical trials When I first entered the clinical research industry more than 20 years ago, trials

Walgreens Boots Alliance appoints Anthony Hemmerdinger as MD, UK and Ireland Walgreens Boots Alliance has announced the appointment of Anthony Hemmerdinger as Managing Director of Boots UK and Ireland.

The new Dementia Trials Accelerator is set to receive £20m of government funding The Dementia Trials Accelerator, led by the UK Dementia Research Institute

Heart failure accounted for approximately 90,000 hospital admissions in England in 2019 to 2020 The National Institute for Health and Care Excellence (NICE) has

Approximately 8.2 million people were diagnosed with the infectious disease in 2023 The World Health Organization’s (WHO) newly published report has placed tuberculosis (TB)

CAL101 shows promising results and is set to enter phase 2 development Calluna Pharma AS has announced the successful completion of Phase 1 clinical

danicopan shown to improve haemoglobin levels and reduce anaemia Alexion, AstraZeneca Rare Disease, announced that the National Institute for Health and Care Excellence (NICE)

Chiesi Group has appointed Laura Vergani as SVP of Global Communications Chiesi Group has announced that Laura Vergani has joined as Senior Vice President

New treatment option for patients with newly diagnosed multiple myeloma The European Commission has approved the subcutaneous (SC) formulation of DARZALEX (daratumumab) in combination

Innovative Trials has appointed Ian Keith as Finance and Business Services Director Innovative Trials has appointed Ian Keith, who has been supporting the company

The company’s workforce will volunteer and fundraise for Team Jak throughout the year Valneva Scotland has partnered with Team Jak, a West Lothian-headquartered charity

The five new programmes are designed to fit alongside full-time work and clinical practice Learna and the University of Wolverhampton have partnered to launch

Primary open-angle glaucoma affects around 2% of adults aged 40 years and older in the UK The National Institute for Health and Care Excellence

Phase 2 study of TG4001 shows promise in cervical cancer patients Transgene, a biotech company specializing in virus-based immunotherapies for cancer, has announced that

The two-year programme will use virtual reality technology to teach essential skills A £4.5m initiative has been launched to address the growing skills shortage

The London hub is home to life sciences companies including Novartis, Engitix and invoX Pharma Vivan Therapeutics has signed a new five-year lease at

NK:IO has appointed Richard Hopkins as Chief Executive Officer NK:IO has appointed Richard Hopkins, an experienced biologics developer, as its new Chief Executive Officer.

There are around 55,100 new prostate cancer cases in the UK every year HBC Immunology (HBCI) has announced that an oral formulation of its

Study reveals potential new strategy for managing inflammatory bowel disease

Partnership to harness AI for DUB-focused preclinical programmes

Acquisition to enhance Lundbeck’s neuroscience pipeline Lundbeck has announced a significant step forward in its Focused Innovator strategy with the acquisition of Longboard Pharmaceuticals.

New vaccine aims to protect older adults from severe flu complications Sanofi has announced the launch of its high-dose egg-based quadrivalent influenza vaccine (QIV-HD)

Teclistamab offers hope for patients exhausting treatment options Teclistamab (Tecvayli), a drug manufactured by Johnson & Johnson, has received a positive recommendation from NICE

Sheffield cardiologists demonstrate cutting-edge TAVI procedure Cardiologists at Sheffield Teaching Hospitals NHS Foundation Trust have performed a cutting-edge heart valve replacement procedure live to

New investment to advance gene therapies for kidney diseases Purespring Therapeutics has raised £80m in an oversubscribed Series B financing round. Syncona Ltd, a

AviadoBio to receive up to £1.8 billion in potential payments AviadoBio and Astellas Pharma have entered into an exclusive option and licence agreement for

Real-world studies show effectiveness of mogamulizumab in routine practice Kyowa Kirin International (KKI) has announced positive interim findings from three real-world studies on mogamulizumab

Scottish Medicines Consortium recommends pembrolizumab The Scottish Medicines Consortium (SMC) has recommended MSD’s KEYTRUDA (pembrolizumab) as a monotherapy for adults with non-small cell lung

Biotech company moves forward with phase 2 trial for precision cancer surgery Copenhagen-based biotech company FluoGuide A/S has announced the submission of a Clinical

Largest real-world study demonstrates significant survival advantage In a landmark study, Johnson & Johnson has announced that ERLEADA (apalutamide) significantly reduces the risk of

Phase 1 trial of IRL757 demonstrates good absorption and safety profile IRLAB Therapeutics AB has announced the successful completion of the first part of

Preclinical data on NeuroRestore therapy to be showcased at CTAD in Madrid AlzeCure Pharma AB, a company specializing in drugs for nervous system diseases,

ISM001-055 shows promise in improving lung function among patients Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, has announced positive preliminary results from

Janssen-Cilag therapy becomes the first single tablet combination therapy for PAH in europe The European Commission has approved Yuvanci (macitentan 10 mg and tadalafil

ICON celebrates 2024 ‘company of the year’ win ICON continues to celebrate its achievement at the 2024 Clinical Researcher of the Year Awards, where

Harnessing vital patient data for precision in clinical trials In clinical research, leveraging patient data has become a critical factor to improve the design,

Sphere Fluidics has appointed Dr Alex Dickinson to its Board of Directors Sphere Fluidics has announced the appointment of Dr Alex Dickinson to its Board of Directors

minds + assembly has appointed Fabio Gratton as an Advisor minds + assembly welcomes Fabio Gratton as an Advisor to its Board of Directors.

New government scheme to offer routine opt-out blood tests Starting next week, Sheffield’s Northern General Hospital A&E Department will begin routine opt-out testing for

£3m programme to accelerate new antimicrobial treatment Oxford Drug Design has been awarded a share of a £3 million Collaborative Discovery Programme (CDP) by

4basebio has announced Dr Amy Walker as Chief Operating Officer 4basebio has announced the appointment of Dr Amy Walker as Chief Operating Officer of

International trial marks leap forward in chemotherapy-induced neuropathy care In a landmark announcement from Paris, AlgoTherapeutix (AlgoTx) has heralded the successful completion of its

International think tanks to shape future of cancer research funding Cancer Grand Challenges, a pioneering initiative co-founded by Cancer Research UK and the US

Milieu Insight has appointed Sundip Chahal as Chief Executive Officer Milieu Insight has appointed Sundip Chahal (pictured left), former YouGov Global Chief Operating Officer,

There is currently no national screening programme for the disease in the UK Oncologica has developed a urine-based screening test for prostate cancer and

The conference will return to Vienna AirportCity on 23 to 24 October 2024 Samedan has announced that on 23 to 24 October 2024, its

It is hoped that the tool will improve the diagnostic pathway and free up radiologists’ time Leeds Teaching Hospitals NHS Trust (LTHT) has announced

Alchemab has appointed Jane Osbourn as Chief Executive Officer Alchemab Therapeutics has appointed Jane Osbourn, the company’s Co-Founder and Chief Scientific Officer, as Chief